Anderson S, Carrico J, Brodtkorb T-H, Lalla D, Brufsky A. Budget impact of introducing neratinib for third-line treatment of HER2+ metastatic breast cancer in the United States. Poster presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting; December 9, 2020.